ATE451835T1 - Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae - Google Patents
Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridaeInfo
- Publication number
- ATE451835T1 ATE451835T1 AT00965349T AT00965349T ATE451835T1 AT E451835 T1 ATE451835 T1 AT E451835T1 AT 00965349 T AT00965349 T AT 00965349T AT 00965349 T AT00965349 T AT 00965349T AT E451835 T1 ATE451835 T1 AT E451835T1
- Authority
- AT
- Austria
- Prior art keywords
- patient
- compositions
- viruses
- protein
- therapeutic methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15587399P | 1999-09-24 | 1999-09-24 | |
| PCT/US2000/026116 WO2001020989A1 (en) | 1999-09-22 | 2000-09-22 | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE451835T1 true ATE451835T1 (de) | 2010-01-15 |
Family
ID=22557120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00965349T ATE451835T1 (de) | 1999-09-24 | 2000-09-22 | Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1217891B1 (de) |
| AT (1) | ATE451835T1 (de) |
| AU (1) | AU7607900A (de) |
| CA (1) | CA2383276A1 (de) |
| DE (1) | DE60043547D1 (de) |
| WO (1) | WO2001020989A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241617B2 (en) | 1998-07-03 | 2007-07-10 | Dnavec Research, Inc. | Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci |
| CA2322057A1 (en) | 2000-05-18 | 2001-11-18 | Dnavec Research Inc. | Paramyxovirus vectors used for transfer of foreign genes |
| CA2484538C (en) | 2002-04-30 | 2014-03-25 | Dnavec Research Inc. | Vectors with modified protease-dependent tropism |
| AU2003234342A1 (en) * | 2002-05-03 | 2003-11-17 | Mayo Foundation For Medical Education And Research | Ablated slam-dependent entry |
| CA2802143C (en) | 2003-01-14 | 2018-06-19 | Dana-Farber Cancer Institute | Sparc encoding polynucleotide as a cancer therapy sensitizer |
| WO2004111249A2 (en) * | 2003-06-13 | 2004-12-23 | Polymun Scientific Immunbiologische Forschung Gmbh | Protein constructs containing caspase recognition sites |
| RU2376371C2 (ru) | 2003-06-18 | 2009-12-20 | Дженелюкс Корпорейшн | Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение |
| JP2007512008A (ja) * | 2003-11-24 | 2007-05-17 | ノボ ノルディスク アクティーゼルスカブ | 融合タンパク質及び該タンパク質の切断方法 |
| WO2005071085A1 (ja) * | 2004-01-22 | 2005-08-04 | Dnavec Research Inc. | ウイルスベクターの製造方法 |
| US8420603B2 (en) | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| CN101875919A (zh) | 2004-11-12 | 2010-11-03 | 拜耳先灵医药股份有限公司 | 重组新城疫病毒 |
| CN101160321A (zh) | 2005-02-18 | 2008-04-09 | 阿布拉西斯生物科学公司 | Q3 sparc缺失突变体及其用途 |
| EP2251034B1 (de) | 2005-12-02 | 2018-02-14 | Icahn School of Medicine at Mount Sinai | Chimäre newcastle disease viren zur präsentation von nicht -nativen oberflächenproteinen und deren verwendung |
| WO2008100292A2 (en) | 2006-10-16 | 2008-08-21 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| KR20100082837A (ko) * | 2007-09-11 | 2010-07-20 | 사파이어 에너지, 인크. | 광합성 생물들에 의한 분자 생산 |
| EP2085092A1 (de) | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Abgeschwächte onkolytische Paramyxoviren zur Kodierung von Vogel-Zytokinen |
| EP2085479A1 (de) | 2008-01-31 | 2009-08-05 | Institut Pasteur | Reverse Genetik von Negativstrang-RNA-Viren in Hefe |
| US20090208495A1 (en) * | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| ES2550179T3 (es) | 2009-02-05 | 2015-11-05 | Icahn School Of Medicine At Mount Sinai | Virus quiméricos de la enfermedad de Newcastle y usos de los mismos |
| EP2579884B1 (de) * | 2010-06-10 | 2014-06-04 | Intervet International B.V. | Antitumorzusammensetzung |
| AU2013212068B2 (en) * | 2012-01-26 | 2018-02-15 | Life Technologies Corporation | Methods for increasing the infectivity of viruses |
| KR20140128966A (ko) * | 2012-01-26 | 2014-11-06 | 라이프 테크놀로지스 코포레이션 | 바이러스의 감염성을 증가시키는 방법 |
| AU2014241843B2 (en) | 2013-03-14 | 2019-05-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| CN106163532B (zh) | 2013-09-03 | 2019-12-31 | 免疫医疗有限公司 | 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法 |
| CN107073099B (zh) | 2014-02-27 | 2022-09-27 | 默沙东公司 | 用于治疗癌症的联合方法 |
| GB2583296A (en) * | 2015-01-05 | 2020-10-21 | Seagull Biosolutions Pvt Ltd | Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| ES2995014T3 (en) | 2017-05-16 | 2025-02-05 | Mayo Found Medical Education & Res | Modified viruses |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| WO2025088124A1 (en) | 2023-10-27 | 2025-05-01 | Boehringer Ingelheim International Gmbh | Novel assay for determining infectious virus titer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9514368D0 (en) | 1995-07-13 | 1995-09-13 | Medical Res Council | Improvements in or relating to binding assays |
| ATE181112T1 (de) * | 1995-08-09 | 1999-06-15 | Schweiz Serum & Impfinst | Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren |
| US6264957B1 (en) * | 1995-09-27 | 2001-07-24 | The United States Of America As Represented By The Department Of Health And Human Services | Product of infectious respiratory syncytial virus from cloned nucleotide sequences |
-
2000
- 2000-09-22 AU AU76079/00A patent/AU7607900A/en not_active Abandoned
- 2000-09-22 DE DE60043547T patent/DE60043547D1/de not_active Expired - Lifetime
- 2000-09-22 WO PCT/US2000/026116 patent/WO2001020989A1/en not_active Ceased
- 2000-09-22 EP EP00965349A patent/EP1217891B1/de not_active Expired - Lifetime
- 2000-09-22 CA CA002383276A patent/CA2383276A1/en not_active Abandoned
- 2000-09-22 AT AT00965349T patent/ATE451835T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1217891A1 (de) | 2002-07-03 |
| DE60043547D1 (de) | 2010-01-28 |
| EP1217891B1 (de) | 2009-12-16 |
| WO2001020989A1 (en) | 2001-03-29 |
| AU7607900A (en) | 2001-04-24 |
| WO2001020989A9 (en) | 2002-10-03 |
| CA2383276A1 (en) | 2001-03-29 |
| EP1217891A4 (de) | 2004-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE451835T1 (de) | Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae | |
| ATE231549T1 (de) | Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung | |
| Sambhi et al. | Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. | |
| Merigan et al. | Purification and characterization of vertebrate interferons | |
| ATE91630T1 (de) | Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren. | |
| DE69914932D1 (de) | Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis | |
| NO20013701D0 (no) | HER-2/neu-fusjonsproteiner | |
| DE69835085D1 (de) | Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor | |
| DK1266006T3 (da) | Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier | |
| ATE335831T1 (de) | Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis | |
| RU95115239A (ru) | Аналог эритропоэтина | |
| RU2001117230A (ru) | Пептиды, ингибирующие трансформирующий фактор роста tgf$$$1 | |
| DK1749836T3 (da) | Rekombinant vaskulær endothelcellevækstfaktor D | |
| WO1995026411A3 (en) | Composition and methods for creating syngeneic recombinant virus-producing cells | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| JP2014509197A (ja) | 標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用 | |
| DE69534600D1 (de) | Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus | |
| DK11187D0 (da) | Dna-sekvenser der koder for proteiner med husi-type i inhibitorers biologiske aktivitet, biotekniske fremgangsmaader til fremstilling af proteinerne o g farmaceutiske praeparater der indeholder dem | |
| CY1107431T1 (el) | Σωματιδια για γoνιδιακη θεραπεια | |
| ATE349225T1 (de) | Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv | |
| GB2161487A (en) | Interferon epsilon | |
| DE69627526D1 (de) | Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung | |
| Hofacre et al. | Efficient therapeutic protein expression using retroviral replicating vector with 2A peptide in cancer models | |
| Ahmed et al. | In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery | |
| EP0236977A3 (de) | Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |